

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

**(1) FURTHER DELAY IN DESPATCH OF CIRCULAR;
(2) POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING;
AND
(3) CHANGE OF BOOK CLOSURE PERIOD**

A. FURTHER DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of Shanghai Henlius Biotech, Inc. (the “**Company**”) dated 17 November 2022 (the “**Announcement**”) in relation to the connected transactions and continuing connected transactions in relation to the License Agreement and the announcement of the Company dated 1 December 2022 (the “**Delay Announcement**”) in relation to the delay in despatch of the Circular. Capitalised terms used in this section A shall have the same meanings as those defined in the Announcement unless the context otherwise requires.

As disclosed in the Delay Announcement, the Circular containing further information regarding the transaction is expected to be despatched to the Shareholders on or about 9 December 2022.

As additional time is required to finalise certain information to be included in the Circular, the Company will despatch the Circular on 13 December 2022.

B. POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING AND CHANGE OF BOOK CLOSURE PERIOD

Reference is also made to the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) and the circular dated 1 December 2022 (the “**Circular**”) issued by the Company. Capitalised terms used in this section B shall have the same meanings as those defined in the Notice and the Circular unless otherwise defined.

Pursuant to the Notice, the EGM is originally scheduled to be held at 8:00 a.m. on Tuesday, 20 December 2022. As the Company needs more time to supplement and perfect the information to be proposed to the EGM for consideration and approval, after careful consideration, the Company has decided to postpone the EGM to 11:00 a.m. on Tuesday, 27 December 2022 (the “**Adjourned EGM**”) in order to allow time for the preparation of the EGM.

The register of members of the Company is originally scheduled to be closed from Monday, 19 December 2022 to Tuesday, 20 December 2022 (both dates inclusive), in order to determine the identity of the shareholders of the Company (the “**Shareholders**”) who will be entitled to attend and vote at the EGM. As a result of the Adjourned EGM, the register of members of the Company will now be closed from Thursday, 22 December 2022 to Tuesday, 27 December 2022 (both days inclusive) in order to determine the identity of the Shareholders who will be entitled to attend and vote at the EGM, during which period no transfer of shares of the Company will be effected. Shareholders whose names appear on the registers of members of the Company on Tuesday, 27 December 2022 shall be entitled to attend and vote at the EGM. In order to qualify for attending and voting at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration by 4:30 p.m. on Wednesday, 21 December 2022.

The form of proxy (the “**Proxy Form**”) sent together with the Notice will remain valid and applicable for use at the Adjourned EGM. Shareholders or authorised persons who have yet to deposit the Proxy Form and a notarially certified copy of the power of attorney or other authority (if the proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority) are required to complete and deposit the Proxy Form and a notarially certified copy of the power of attorney or other authority (if the proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority) in accordance with the instructions printed thereon at the Company’s Board secretary office (for holders of domestic shares or unlisted foreign shares), at 9th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC or the Company’s H share registrar in Hong Kong (for holders of H shares), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time appointed for the Adjourned EGM. For the avoidance of doubt, any Proxy Form duly completed and deposited in accordance with the instructions printed thereon remains valid for the Adjourned EGM and the relevant Shareholders are not required to deposit another Proxy Form. If any Shareholder chooses to re-submit the Proxy Form, the last Proxy Form received will revoke and supersede the Proxy Form previously submitted by such Shareholder.

Save as disclosed in this announcement, all other information and content contained in the Notice and the Circular remains unchanged.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 9 December 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive Directors.